AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9439150 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole added to chemotherapy (5-fluorouracil 1,000 mg/m2/day for 5 days and cisplatin 60 mg/m2 for 1 day)
Number of subjects: 100
Study 9439150 — intervention group
Group type: COMPARATOR
Intervention: Non-levamisole group (5-fluorouracil 1,000 mg/m2/day for 5 days and cisplatin 60 mg/m2 for 1 day)
Number of subjects: 100
Study 9439150 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole added to chemotherapy
Number of subjects: 100
Study 9439150 — intervention group
Group type: COMPARATOR
Intervention: Non-levamisole group
Number of subjects: 100
Study 8507222 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin in RA patients
Number of subjects: 1616
Study 8507222 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac in OA patients
Number of subjects: 1616
Study 8507222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1616
Study 8507222 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin in OA patients
Number of subjects: 1616
Study 3565302 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g xylitol
Number of subjects: 0
Study 3565302 — intervention group
Group type: COMPARATOR
Intervention: Glucose, fructose, or sucrose preload
Number of subjects: 0
Study 30376088 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV
Number of subjects: 333
Study 30376088 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV with bOPV
Number of subjects: 333
Study 30376088 — intervention group
Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 333
Study 30376088 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (A, B, C)
Number of subjects: 333
Study 27404643 — intervention group
Group type: EXPERIMENTAL
Intervention: Spice MyPlate intervention (6-week school-based intervention focusing on cooking with spices and herbs)
Number of subjects: 110
Study 27404643 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition education (control group)
Number of subjects: 110
Study 24764677 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) - 3 times weekly for 3 months, including exercises like leg press, chest press, seated rowing, latissimus pull down, with 8-12 repetitions, 3 sets for each exercise, total duration of 40 min.
Number of subjects: 82
Study 24764677 — intervention group
Group type: COMPARATOR
Intervention: Control (Stretching) - Home stretching for 3 months.
Number of subjects: 82
Study 22945703 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Phosphate (Aegis‐ Opaque White, Bosworth Co. Ltd.)
Number of subjects: 30
Study 22945703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride containing (Teethmate F1 Natural Clear, Kuraray Co. Ltd.)
Number of subjects: 30
Study 22945703 — intervention group
Group type: COMPARATOR
Intervention: Resin based (Concise‐ Opaque White, 3M ESPE Co. Ltd.)
Number of subjects: 30
Study 20101197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous heparin at 10 units/kg/hr
Number of subjects: 90
Study 20101197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20101197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous heparin at 10 units/kg/hr (aged <30 days)
Number of subjects: 90
Study 20101197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aged <30 days)
Number of subjects: 90
Study 20101197 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters in place > or = 7 days
Number of subjects: 90
Study 18662199 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (vendor-supported trials)
Number of subjects: 18
Study 18662199 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (non-vendor-supported trials)
Number of subjects: 18
Study 16000966 — intervention group
Group type: EXPERIMENTAL
Intervention: REST routine treatment group
Number of subjects: 164
Study 16000966 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 164
Study 14518795 — intervention group
Group type: EXPERIMENTAL
Intervention: Free load lifting (light, medium, heavy)
Number of subjects: 13
Study 14518795 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic lifting (slow, medium, fast)
Number of subjects: 13
Study 10759091 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 400 mg/day)
Number of subjects: 312
Study 10759091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 8828525 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of H1-receptor antagonist (azelastine)
Number of subjects: 24
Study 8828525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1520649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion at 9.25 micrograms/kg/min over 24 hours
Number of subjects: 20
Study 1520649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 20
Study 1520649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6335859 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 13
Study 6335859 — intervention group
Group type: COMPARATOR
Intervention: Placebo TNS (transcutaneous nerve stimulation)
Number of subjects: 13
Study 30840623 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI with frontal-executive dysfunction (FED)
Number of subjects: 85
Study 30840623 — intervention group
Group type: COMPARATOR
Intervention: MCI without frontal-executive dysfunction (FED)
Number of subjects: 85
Study 30840623 — intervention group
Group type: COMPARATOR
Intervention: Cognitively normal elderly (CNE)
Number of subjects: 85
Study 30840623 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI groups (both with and without FED)
Number of subjects: 85
Study 30840623 — intervention group
Group type: COMPARATOR
Intervention: CNE group
Number of subjects: 85
Study 29209783 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise session
Number of subjects: 22
Study 29209783 — intervention group
Group type: COMPARATOR
Intervention: Reference session
Number of subjects: 22
Study 26986995 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 5 mg kg(‐1) intravenous (i.v.) every 36 h
Number of subjects: 96
Study 26986995 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosage of gentamicin
Number of subjects: 96
Study 23427280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 375 mg twice daily orally plus intravenous amiodarone
Number of subjects: 41
Study 23427280 — intervention group
Group type: COMPARATOR
Intervention: Intravenous amiodarone alone
Number of subjects: 41
Study 22993421 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of MPH
Number of subjects: 40
Study 22993421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20171613 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification/warming
Number of subjects: 0
Study 20171613 — intervention group
Group type: COMPARATOR
Intervention: Slow-rate freezing/thawing
Number of subjects: 0
Study 17919329 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatric assessment
Number of subjects: 37
Study 17919329 — intervention group
Group type: COMPARATOR
Intervention: Face to face interviews
Number of subjects: 37
Study 16289796 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile of Chronic Pain: Extended Assessment Battery (PCP:EA)
Number of subjects: 0
Study 12176866 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Number of subjects: 228
Study 12176866 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 228
Study 10454703 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intravenous infusion of amino acids (Freamine 8.5% III, Baxter)
Number of subjects: 26
Study 8554929 — intervention group
Group type: EXPERIMENTAL
Intervention: Stethoscope auscultation (SBPa, DBPa‐IV, DBPa‐V)
Number of subjects: 8
Study 8554929 — intervention group
Group type: EXPERIMENTAL
Intervention: Stethoscope auscultation (DBPa‐IV)
Number of subjects: 8
Study 8554929 — intervention group
Group type: EXPERIMENTAL
Intervention: Stethoscope auscultation (DBPa‐V)
Number of subjects: 8
Study 8554929 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometry (SBPo)
Number of subjects: 8
Study 8554929 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometry (DBPo)
Number of subjects: 8
Study 8554929 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger pulse pressure (DBPf)
Number of subjects: 8
Study 8554929 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger pulse pressure (SBPf)
Number of subjects: 8
Study 2316590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) every 4 hours
Number of subjects: 31
Study 6299842 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage vaccine
Number of subjects: 121
Study 6299842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage vaccine
Number of subjects: 121
Study 6299842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients
Number of subjects: 121
Study 6299842 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recurrent herpetic disease
Number of subjects: 121
Study 31747967 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-anodal tDCS (n = 20)
Number of subjects: 60
Study 31747967 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-cathodal tDCS (n = 20)
Number of subjects: 60
Study 31747967 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n = 20)
Number of subjects: 60
Study 30045711 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS intervention
Number of subjects: 1500
Study 30045711 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS+PrEP
Number of subjects: 1500
Study 30045711 — intervention group
Group type: COMPARATOR
Intervention: Control (before DREAMS implementation)
Number of subjects: 1500
Study 26801759 — intervention group
Group type: EXPERIMENTAL
Intervention: AFLY5 intervention
Number of subjects: 2221
Study 26801759 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2221
Study 24388327 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO + vitamin A
Number of subjects: 793
Study 24388327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study 24388327 — intervention group
Group type: COMPARATOR
Intervention: iNO
Number of subjects: 793
Study 21654314 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (loading dose of 500 mg, followed by 250 mg daily) and Sunitinib (50 mg/d for 4 weeks)
Number of subjects: 17
Study 21654314 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (loading dose of 1125 mg, followed by 500 mg daily) and Sunitinib (50 mg/d for 4 weeks)
Number of subjects: 17
Study 21654314 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Number of subjects: 17
Study 21654314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 17
Study 19327620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrates and hydralazine (FDC I/H)
Number of subjects: 352
Study 17533403 — intervention group
Group type: EXPERIMENTAL
Intervention: PVACEBOP multi-agent chemotherapy as primary therapy for high-risk patients (SNLG index >or=0.5)
Number of subjects: 55
Study 17533403 — intervention group
Group type: COMPARATOR
Intervention: Standard ChlVPP or ABVD chemotherapy+/−radiotherapy for standard risk patients (SNLG index <0.5)
Number of subjects: 55
Study 17533403 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (salvage therapy)
Number of subjects: 55
Study 17533403 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (overall survival)
Number of subjects: 55
Study 16447051 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone once daily for 5 days
Number of subjects: 12
Study 16447051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14631456 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam, 15 mg
Number of subjects: 28
Study 14631456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11085962 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 404
Study 11085962 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 404
Study 8856156 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 3000 micrograms t.i.d.
Number of subjects: 0
Study 8856156 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 900 micrograms t.i.d.
Number of subjects: 0
Study 8856156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1503435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (2 mg per dose, 6 times per day for a total of 25 doses)
Number of subjects: 25
Study 1503435 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropyl-beta-cyclodextrin vehicle (placebo)
Number of subjects: 25
Study 1503435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (2 mg per dose, 3 doses daily)
Number of subjects: 25
Study 1503435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pirodavir (24 h after RV challenge)
Number of subjects: 25
Study 6384282 — intervention group
Group type: COMPARATOR
Intervention: Intralesional IFN‐alpha
Number of subjects: 10
Study 6384282 — intervention group
Group type: COMPARATOR
Intervention: Systemic IFN‐alpha
Number of subjects: 10
Study 29135501 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia in addition to standard care
Number of subjects: 386
Study 29135501 — intervention group
Group type: COMPARATOR
Intervention: Control treatments only
Number of subjects: 386
Study 29135501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 386
Study 28236571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 81
Study 28236571 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 81
Study 25053758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedicle conjunctival flap (CF)
Number of subjects: 40
Study 25053758 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved amniotic membrane graft (AMG)
Number of subjects: 40
Study 24030945 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (6.4 nmol/kg, twice-daily subcutaneous injections during menstrual days 7-14)
Number of subjects: 10
Study 24030945 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study 20348438 — intervention group
Group type: EXPERIMENTAL
Intervention: Late microvascular obstruction (MO)
Number of subjects: 100
Study 20348438 — intervention group
Group type: EXPERIMENTAL
Intervention: Early microvascular obstruction (MO)
Number of subjects: 100
Study 20348438 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline infarct volume index
Number of subjects: 100
Study 17805229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3 g day(-1), fish oil capsules)
Number of subjects: 52
Study 17805229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (only capsules)
Number of subjects: 52
Study 16148211 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling session
Number of subjects: 77
Study 16148211 — intervention group
Group type: COMPARATOR
Intervention: General health information control session
Number of subjects: 77
Study 12790209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 12790209 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-sufentanil
Number of subjects: 20
Study 10891632 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/Lofexidine combination treatment
Number of subjects: 22
Study 10891632 — intervention group
Group type: COMPARATOR
Intervention: Conventional Lofexidine treatment
Number of subjects: 22
Study 9023716 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril and indapamide
Number of subjects: 6000
Study 9023716 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 6000
Study 9023716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 9023716 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 6000
Study 1893706 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 ug plus norethindrone 0.4 mg
Number of subjects: 51
Study 1893706 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ug ethinyl estradiol plus 1.5 mg norethindrone acetate
Number of subjects: 51
Study 1893706 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone 200 mg daily
Number of subjects: 51
Study 1893706 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 ug plus 1.5 mg norethindrone acetate
Number of subjects: 51
Study 6228504 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A
Number of subjects: 44
Study 6228504 — intervention group
Group type: COMPARATOR
Intervention: Preparation B (comparison group)
Number of subjects: 44
Study 27734203 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 256
Study 27734203 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 256
Study 24415559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) with InterStim Therapy
Number of subjects: 147
Study 24415559 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 147
Study 24415559 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 147
Study 24415559 — intervention group
Group type: COMPARATOR
Intervention: Medication-related adverse events
Number of subjects: 147
Study 24055014 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066 145 mg TID
Number of subjects: 381
Study 24055014 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066 245 mg TID
Number of subjects: 381
Study 24055014 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066 390 mg TID
Number of subjects: 381
Study 24055014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 24055014 — intervention group
Group type: EXPERIMENTAL
Intervention: IPX066 (all dosages)
Number of subjects: 381
Study 22776850 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol triphosphate (RTP)
Number of subjects: 32
Study 22776850 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin-rich grape seed extract (CGSE)
Number of subjects: 32
Study 22776850 — intervention group
Group type: COMPARATOR
Intervention: Resveratrol (RES)
Number of subjects: 32
Study 20015903 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intranasal corticosteroids (Mometasone furoate 50 microg)
Number of subjects: 217
Study 20015903 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 217
Study 17538170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vinorelbine plus cisplatin)
Number of subjects: 172
Study 17538170 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 172
Study 15293483 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS and exercise training
Number of subjects: 62
Study 15293483 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 62
Study 15293483 — intervention group
Group type: COMPARATOR
Intervention: Exercise training
Number of subjects: 62
Study 15293483 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 62
Study 11215868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 9
Study 11215868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9147422 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug regimen (clarithromycin 500 mg twice daily and ethambutol 800-1,000 mg daily)
Number of subjects: 106
Study 9147422 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen (clarithromycin 500 mg twice daily, ethambutol 800-1,000 mg daily, and clofazimine 100 mg daily)
Number of subjects: 106
Study 7505008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic asthma
Number of subjects: 0
Study 7505008 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial ICAM‐1 expression
Number of subjects: 0
Study 7505008 — intervention group
Group type: COMPARATOR
Intervention: Allergen challenge
Number of subjects: 0
Study 7505008 — intervention group
Group type: COMPARATOR
Intervention: Epithelial ICAM‐1 expression after allergen challenge
Number of subjects: 0
Study 7505008 — intervention group
Group type: EXPERIMENTAL
Intervention: VCAM‐1 and ICAM‐1 expression after allergen challenge
Number of subjects: 0
Study 2881786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.1-0.2 microgram kg-1 min-1)
Number of subjects: 7
Study 2881786 — intervention group
Group type: COMPARATOR
Intervention: Pindolol (beta-adrenergic blocker)
Number of subjects: 7
Study 2881786 — intervention group
Group type: COMPARATOR
Intervention: Practolol (beta-adrenergic blocker)
Number of subjects: 7
Study 30223721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation therapy
Number of subjects: 46
Study 27504914 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every-other-week (following a single 80 mg dose)
Number of subjects: 425
Study 27504914 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab (any time during the study)
Number of subjects: 425
Study 26422980 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 227
Study 26422980 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation
Number of subjects: 227
Study 26422980 — intervention group
Group type: EXPERIMENTAL
Intervention: PTNS
Number of subjects: 227
Study 26422980 — intervention group
Group type: COMPARATOR
Intervention: PTNS and Sham
Number of subjects: 227
Study 23555855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) for 16 weeks (20 minutes three times per week)
Number of subjects: 135
Study 23555855 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC) program of equal length and structure, involving viewing short documentaries about the natural world
Number of subjects: 135
Study 22100175 — intervention group
Group type: EXPERIMENTAL
Intervention: B-Twin® spacer
Number of subjects: 50
Study 22100175 — intervention group
Group type: COMPARATOR
Intervention: Corset
Number of subjects: 50